Voyager Therapeutics (VYGR) Accumulated Depreciation & Amortization (2016 - 2025)
Voyager Therapeutics (VYGR) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $19.2 million as the latest value for Q4 2025.
- Quarterly Accumulated Depreciation & Amortization rose 20.01% to $19.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.2 million through Dec 2025, up 20.01% year-over-year, with the annual reading at $19.2 million for FY2025, 20.01% up from the prior year.
- Accumulated Depreciation & Amortization hit $19.2 million in Q4 2025 for Voyager Therapeutics, up from $16.0 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $19.2 million in Q4 2025 to a low of $15.0 million in Q4 2023.
- Historically, Accumulated Depreciation & Amortization has averaged $16.7 million across 5 years, with a median of $16.0 million in 2024.
- Biggest five-year swings in Accumulated Depreciation & Amortization: soared 37.54% in 2021 and later fell 12.61% in 2023.
- Year by year, Accumulated Depreciation & Amortization stood at $15.9 million in 2021, then increased by 8.13% to $17.2 million in 2022, then fell by 12.61% to $15.0 million in 2023, then rose by 6.12% to $16.0 million in 2024, then grew by 20.01% to $19.2 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for VYGR at $19.2 million in Q4 2025, $16.0 million in Q4 2024, and $15.0 million in Q4 2023.